Business Context and Reporting Period
This Form 6-K filing by Bionomics Limited (not Neuphoria Therapeutics Inc.) covers the period ended December 31, 2022, and was filed on January 30, 2023. The document serves to furnish the Company's Appendix 4C Quarterly Cashflow Report, which was released to the Australian Securities Exchange (ASX) in compliance with Australian regulations.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document acts as a cover sheet referencing an attached exhibit (Exhibit 99.1) containing the actual financial data, but the numerical details of that exhibit are not included in the provided text.
Material Changes
The filing text does not provide a clear value or description of material changes versus the prior comparable period. It only confirms the submission of the quarterly cashflow report for the period ended December 31, 2022.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, guidance, outlook, risks, contingencies, or unusual items. The content is limited to the administrative details of the filing and the signature of the Chairman, Errol De Souza, Ph.D.
Investor Verification Checklist
- Verify the actual financial figures by reviewing Exhibit 99.1 (Quarterly Report for the Period Ended December 2022), as the summary text contains no numerical data.
- Confirm the company identity is Bionomics Limited, noting the discrepancy with the "Neuphoria Therapeutics Inc." name in the request metadata.
- Check the ASX release dated January 30, 2023, for the full Appendix 4C details.